Dianthus Therapeutics, Inc. /DE/
DNTHDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How DNTH's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DNTH103 | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Frequently asked questions
What is in Dianthus Therapeutics, Inc. /DE/'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Dianthus Therapeutics, Inc. /DE/'s (DNTH) pipeline across Phase 3. Its lead program is DNTH103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dianthus Therapeutics, Inc. /DE/'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Dianthus Therapeutics, Inc. /DE/ (DNTH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DNTH biotech catalysts?→
Add DNTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dianthus Therapeutics, Inc. /DE/'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.